Moleculin Biotech, Inc. (MBRX)
The company now
Moleculin Biotech is classed as a pre-revenue company with no meaningful revenue on file yet and operates in the Pharmaceutical Preparations industry (SIC 2834) Capital expenditure was zero across the filed record 52
From the record in brief, written by the desk, an AI model, from the company's record on Oct 23, 2026. Nothing here is advice.
Where the revenue comes from
No split of its revenue is on file yet.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
five sections from the recordBy the desk, an AI model (Claude Haiku 4.5), written from the company's record on Oct 23, 2026; nothing here is advice. Every sentence rests on the numbered source beside it, and a sentence the record did not support was cut before the report was kept.
A newer current report (Form 8-K, filed 2026-11-12) is on file; this report was written before it, and the desk writes it again on request.
Past
Moleculin Biotech reported no net income profit in any of its 9 filed years The company's net worth remained at 15 million dollars from 2016 to 2025, while it accumulated minus 190 million dollars in profit kept over that span The company carried out a 1-for-15 reverse split in 2024 The past grade reads 6.3 of 10 1345
Present
For the fiscal year ended 2025-12-31, Moleculin reported revenue of zero and a loss of 34 million dollars Return on equity stood at minus 224 percent, meaning the company lost 224 cents for every dollar of shareholders' money; leverage was 32 cents owed per dollar of assets; and the share count grew 760.1 percent over the year Book value per share was 12.67 dollars on 1 million diluted average shares for fiscal 2025 Walter V Klemp serves as CEO and President, filing under that title since 2016-06-07 for 10.4 years; the 8 officers and directors filing in the last fifteen months have a median tenure of 10.2 years; 3 officer or director changes were reported on Form 8-K since 2023-10-22 against the 8 people in charge now The present grade reads 4.8 of 10 513
Future
The quarterly report for the quarter ending 2026-09-30 is due by 2026-11-14 under the SEC's rules for non-accelerated filers and smaller reporting companies The annual report for the fiscal year ending 2026-12-31 is due by 2027-03-31 under the SEC's rules for non-accelerated filers and smaller reporting companies The future grade reads 4.5 of 10 65
How the company operates
Moleculin Biotech is classed as a pre-revenue company with no meaningful revenue on file yet and operates in the Pharmaceutical Preparations industry (SIC 2834) Capital expenditure was zero across the filed record 52
New moves
On 2026-10-20, the company filed a Form 8-K reporting a change to shareholders' rights, a change to the charter, bylaws or fiscal year, and another event it chose to report On 2026-10-16, the company filed a Form 8-K with an investor disclosure under Regulation FD On 2026-10-15, the company filed a Form S-8 to register shares set aside for employee stock plans On 2026-10-09, the company filed a Form 8-K reporting an officer or director change and shareholder vote results On 2026-09-18, the company filed a Form 8-K reporting a listing warning from its exchange 6
Sources
a number beside a sentence opens its entry in its own document's listThe record in brief 6 sources · written Oct 23, 2026
- MBRX: the nine metricsthis site's record
show the quoted words
Track record (past, graded 5.8 of 10, weighs 45% of the past): Moleculin Biotech, Inc.'s 9 filed years say what it did: it never fell from a peak; net income was positive in 0 of 9 of those years (its annual reports). Finding: 9 filed years; profitable in 0 of 9.
Financial health (present, graded 2.4 of 10, weighs 45% of the present): Return on equity: in the fiscal year ended 2025-12-31, Moleculin Biotech, Inc. lost about 224 cents for every dollar of shareholders' money. Leverage: it owed about 32 cents per dollar of assets, and net share issuance: its share count grew 760.1% over the year (the filed statements). Finding: ROE -224%: lost 224¢ per shareho
Leadership (present, graded 7.9 of 10, weighs 33% of the present): Moleculin Biotech, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Klemp, Walter V (CEO and President, as filed), filing under that title since 2016-06-07, 10.4 years (top 16% of its family); the 8 officers and directors filing in the last fifteen months have been on the r
Surviving crises (past, graded 2.1 of 10, weighs 22% of the past): Moleculin Biotech, Inc.'s filings since 2017 show 12 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 9 times, the latest 2026-09-18); an auditor change (8-K item 4.01, the latest 2017-02-23); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2019-08-14) (its current reports).
- MBRX: the money and the checks, as fileda filing
show the quoted words
Revenue by fiscal year (USD billions): 2018 0; 2019 0; 2020 0; 2021 0; 2022 0; 2023 0; 2024 0; 2025 0. Net income (the profit kept) (USD billions): 2018 -0.01; 2019 -0.01; 2020 -0.02; 2021 -0.02; 2022 -0.03; 2023 -0.03; 2024 -0.03; 2025 -0.03.
Research and development (R&D) (USD billions): 2018 0.01; 2019 0.01; 2020 0.01; 2021 0.01; 2022 0.02; 2023 0.02; 2024 0.02; 2025 0.02.
Capital expenditure (capex) (USD billions): 2018 0; 2019 0; 2020 0; 2021 0; 2022 0; 2023 0; 2024 0; 2025 0.
- MBRX: net worth, from the balance sheeta filing
show the quoted words
In fiscal 2016, 9 filed years earlier, the net worth was $15 million, so it has moved about 0% a year up since. Over fiscal 2016 to 2025 it earned minus $190 million in profit kept.
Cash and near-cash $9 million at the same year end.
Book value per share: $12.67 on 1 million diluted average shares for fiscal 2025.
- MBRX: the statements' history (names, splits, dividends per share)a filing
show the quoted words
Changes of share basis: a 1-for-15 reverse split dated by the report that restated it, filed 2024-03-22 (shown by the Form 10-K filed 2024-03-22, which restates fiscal 2022 on the new basis).
- MBRX: the company filethis site's record
show the quoted words
Headline grade 5.1 of 10; the arc reads past 6.3, present 4.8, future 4.5; 4 of 9 metrics read as filed.
In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $0 thousand and a loss of $34 million (its filed statements).
Pre-revenue company (no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it). Sector: Pharmaceutical Preparations (SIC 2834).
- MBRX: the filing record, ten yearsa filing
show the quoted words
Deadline ahead: Quarterly report (Form 10-Q) for the quarter ending 2026-09-30 is due by 2026-11-14; non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. A deadline under the SEC's rules, not a prediction of when it will file.
Deadline ahead: Annual report (Form 10-K) for the fiscal year ending 2026-12-31 is due by 2027-03-31; non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. A deadline under the SEC's rules, not a prediction of when it will file.
2026-10-20: Form 8-K, Current report (Change to shareholders' rights, item 3.03; Charter, bylaw or fiscal-year change, item 5.03; Other event, item 8.01), for the period ended 2026-10-16. Shareholder treatment: a change to shareholders' rights. Leadership: the charter, bylaws or fiscal year changed. The news lane: another event the company chose to report.
Document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969 2026-10-16: Form 8-K, Current report (Investor disclosure (Regulation FD), item 7.01). The news lane: a disclosure to investors under Regulation FD.
Document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032762 2026-10-15: Form S-8, Employee stock plan registration. The share count: shares set aside for employee plans.
Document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032730 2026-10-09: Form 8-K, Current report (Officer or director change, item 5.02; Shareholder vote, item 5.07). Leadership: the officer or director change count. Leadership and Shareholder treatment: the vote results.
Document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005 2026-09-18: Form 8-K, Current report (Listing warning from its exchange, item 3.01), for the period ended 2026-09-15. Surviving crises: a listing warning from the exchange.